210 related articles for article (PubMed ID: 35363510)
21. Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.
Melotti L; Meco D; Battaglia A; Buzzonetti A; Martini M; Ruggiero A; Scambia G; Riccardi R
Oncol Rep; 2021 Feb; 45(2):752-763. PubMed ID: 33416182
[TBL] [Abstract][Full Text] [Related]
22. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL] [Abstract][Full Text] [Related]
23. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Stathis A; Tolcher AW; Wang JS; Renouf DJ; Chen LC; Suttner LH; Freshwater T; Webber AL; Nayak T; Siu LL
Invest New Drugs; 2023 Jun; 41(3):380-390. PubMed ID: 37040046
[TBL] [Abstract][Full Text] [Related]
24. ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.
Vajapeyam S; Brown D; Ziaei A; Wu S; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Jones BV; Yeom KW; Onar-Thomas A; Dunkel IJ; Fouladi M; Fangusaro JR; Poussaint TY
AJNR Am J Neuroradiol; 2022 Mar; 43(3):455-461. PubMed ID: 35210278
[TBL] [Abstract][Full Text] [Related]
25. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
[TBL] [Abstract][Full Text] [Related]
27. Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.
Boisseau W; Euskirchen P; Mokhtari K; Dehais C; Touat M; Hoang-Xuan K; Sanson M; Capelle L; Nouet A; Karachi C; Bielle F; Guégan J; Marie Y; Martin-Duverneuil N; Taillandier L; Rousseau A; Delattre JY; Idbaih A
Oncologist; 2019 Dec; 24(12):1584-1592. PubMed ID: 31346129
[TBL] [Abstract][Full Text] [Related]
28. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Parsons DW; Janeway KA; Patton DR; Winter CL; Coffey B; Williams PM; Roy-Chowdhuri S; Tsongalis GJ; Routbort M; Ramirez NC; Saguilig L; Piao J; Alonzo TA; Berg SL; Fox E; Hawkins DS; Abrams JS; Mooney M; Takebe N; Tricoli JV; Seibel NL;
J Clin Oncol; 2022 Jul; 40(20):2224-2234. PubMed ID: 35353553
[TBL] [Abstract][Full Text] [Related]
29. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Farley J; Brady WE; Vathipadiekal V; Lankes HA; Coleman R; Morgan MA; Mannel R; Yamada SD; Mutch D; Rodgers WH; Birrer M; Gershenson DM
Lancet Oncol; 2013 Feb; 14(2):134-40. PubMed ID: 23261356
[TBL] [Abstract][Full Text] [Related]
30. Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib.
Campagne O; Yeo KK; Fangusaro J; Stewart CF
Clin Pharmacokinet; 2021 Mar; 60(3):283-303. PubMed ID: 33354735
[TBL] [Abstract][Full Text] [Related]
31. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Chae YK; Hong F; Vaklavas C; Cheng HH; Hammerman P; Mitchell EP; Zwiebel JA; Ivy SP; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Mansfield A; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Jul; 38(21):2407-2417. PubMed ID: 32463741
[TBL] [Abstract][Full Text] [Related]
32. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
Fangusaro J; Onar-Thomas A; Poussaint TY; Wu S; Ligon AH; Lindeman N; Campagne O; Banerjee A; Gururangan S; Kilburn LB; Goldman S; Qaddoumi I; Baxter P; Vezina G; Bregman C; Patay Z; Jones JY; Stewart CF; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Neuro Oncol; 2021 Oct; 23(10):1777-1788. PubMed ID: 33631016
[TBL] [Abstract][Full Text] [Related]
34. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Rosenberg T; Yeo KK; Mauguen A; Alexandrescu S; Prabhu SP; Tsai JW; Malinowski S; Joshirao M; Parikh K; Farouk Sait S; Rosenblum MK; Benhamida JK; Michaiel G; Tran HN; Dahiya S; Kachurak K; Friedman GK; Krystal JI; Huang MA; Margol AS; Wright KD; Aguilera D; MacDonald TJ; Chi SN; Karajannis MA
Neuro Oncol; 2022 Nov; 24(11):1964-1975. PubMed ID: 35397478
[TBL] [Abstract][Full Text] [Related]
35. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
[TBL] [Abstract][Full Text] [Related]
36. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract][Full Text] [Related]
37. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
38. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
[TBL] [Abstract][Full Text] [Related]
39. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
40. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
